12:00 AM
 | 
May 05, 2014
 |  BioCentury  |  Emerging Company Profile

Sensulin: Sensing sugar

Sensulin's glucose-activated insulin provides 24-hour blood sugar control

Insulin-dependent diabetics take a combination of basal and prandial insulins two or more times a day to manage fluctuations in blood sugar, especially at mealtime. Sensulin LLC is developing a glucose-responsive once-daily insulin that could mimic insulin release in healthy people and eliminate the need for multiple injections.

Basal insulins are taken once a day, and prandial insulins are added at mealtimes, or whenever a surge in glucose is expected. There are premixed products that combine prandial and basal insulin; however, they require twice-daily injections to maintain basal insulin levels.

Sensulin is using its agglomerate vesicle technology (AVT) to control the delivery of insulin in response to changing levels of glucose.

AVT is based upon liposomes that are linked by a stimulus-responsive molecule. The liposomes can be used to encapsulate a variety of drugs, and the stimulus-responsive molecules can be designed to be triggered by a variety of stimuli.

The AVT insulin...

Read the full 741 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >